Abstracts Archive - Page 1513 of 2607 - ACR Meeting Abstracts

Abstract Number: 1886 • 2017 ACR/ARHP Annual Meeting
Continued Fracture Risk Reduction after 12 Months of Romosozumab Followed By Denosumab through 36 Months in the Extension of the Phase 3 Fracture Study in Postmenopausal Women with Osteoporosis
E Michael Lewiecki¹, Rajani V Dinavahi², Marise Lazaretti-Castro³, Peter R Ebeling⁴, J Adachi⁵, Akimitsu Miyauchi⁶, Evelien Gielen⁷, Cassandra E Milmont², Cesar Libanati⁸ and Andreas Grauer², ¹New Mexico Clinical Research & Osteoporosis Center, Albuquerque, NM, ²Amgen Inc., Thousand Oaks, CA, ³Federal University of São Paulo, São Paulo, Brazil, ⁴Monash University, Melbourne, Australia, ⁵McMaster University, Hamilton, ON, Canada, ⁶Miyauchi Medical Center, Osaka, Japan, ⁷University Hospitals Leuven, Leuven, Belgium, ⁸UCB Pharma, Brussels, Belgium
Background/Purpose: Romosozumab (Romo) is a monoclonal antibody that binds sclerostin with a dual effect, increasing bone formation and decreasing bone resorption. In the primary analysis…
Abstract Number: 1887 • 2017 ACR/ARHP Annual Meeting
Ten-Year Continued Nonvertebral Fracture Reduction in Postmenopausal Osteoporosis with Denosumab Treatment
S Ferrari¹, PW Butler², DL Kendler³, Paul D Miller⁴, C Roux⁵, AT Wang², Rachel B. Wagman² and EM Lewiecki⁶, ¹Geneva University Hospital, Geneva, Switzerland, ²Amgen Inc., Thousand Oaks, CA, ³University of British Columbia, Vancouver, BC, Canada, ⁴Colorado Center for Bone Research, Lakewood, CO, ⁵Paris Descartes University, Paris, France, ⁶New Mexico Clinical Research & Osteoporosis Center, Albuquerque, NM
Background/Purpose: Treatment with denosumab (DMAb) for 3 years significantly reduces the incidence of nonvertebral fractures (NVFx; Cummings NEJM 2009). While there are limited data describing…
Abstract Number: 1888 • 2017 ACR/ARHP Annual Meeting
Effect of Denosumab Compared with Risedronate on Percentage Change in Lumbar Spine Bone Mineral Density at 12 Months in Subgroups of Glucocorticoid-Treated Individuals
Kenneth Saag¹, N Pannacciulli², P Geusens³, J Adachi⁴, Eric Lespessailles⁵, J Malouf⁶, O Messina⁷, AT Wang², Rachel B. Wagman² and WF Lems⁸, ¹University of Alabama, Birmingham, AL, ²Amgen Inc., Thousand Oaks, CA, ³Maastricht University, Maastricht, Netherlands, ⁴McMaster University, Hamilton, ON, Canada, ⁵University Hospital Orleans, Orleans, France, ⁶Hospital San Pablo, Barcelona, Spain, ⁷Cosme Argerich Hospital, Buenos Aries, Argentina, ⁸VU University Medical Centre, Amsterdam, Netherlands
Background/Purpose: Glucocorticoid (GC)-induced osteoporosis (GIOP) remains the most common secondary cause of osteoporosis. We previously demonstrated that denosumab (DMAb) significantly increased lumbar spine (LS) BMD…
Abstract Number: 1889 • 2017 ACR/ARHP Annual Meeting
Safety and Efficacy of Denosumab Among Subjects with Mild-to-Moderate Chronic Kidney Disease (CKD) in the “Fracture Reduction Evaluation of Denosumab in Osteoporosis Every 6 Months” Extension Study
Aaron Broadwell¹, Peter R Ebeling², Edward Franek³, Stefan Goemaere⁴, Rachel B. Wagman⁵, Xiang Yin⁵, Susan Yue⁵ and Paul D Miller⁶, ¹Rheumatology and Osteoporosis Specialists, Shreveport, LA, ²Monash University, Clayton, Australia, ³Mossakowski Medical Research Centre, Polish Academy of Sciences, Warsaw, Poland, ⁴Ghent University Hospital, Gent, Belgium, ⁵Amgen Inc., Thousand Oaks, CA, ⁶Colorado Center for Bone Research, Lakewood, CO
Background/Purpose: As renal function may decline with age, it is important to understand the safety and efficacy of therapeutic agents for postmenopausal osteoporosis (PMO) and…
Abstract Number: 1890 • 2017 ACR/ARHP Annual Meeting
Persistent Fracture Reduction with Abaloparatide-SC (TYMLOS™) Followed By 24 Months of Alendronate
Kenneth Saag¹, Paul D Miller², Felicia Cosman^3,4, Lorraine A Fitzpatrick⁵, Gary Hattersley⁶, Robert Gut⁶, Bruce Mitlak⁶, John P Bilezikian⁴ and Robin K Dore⁷, ¹Department of Medicine, University of Alabama at Birmingham, Birmingham, AL, ²Colorado Center for Bone Research, Lakewood, CO, ³Helen Hayes Hospital, West Haverstraw, NY, ⁴Columbia University College of Physicians and Surgeons, New York, NY, ⁵Chief Medical Officer, Radius Health, Inc., Waltham, MA, ⁶Radius Health, Inc., Waltham, MA, ⁷Robin K Dore, MD, Inc., Tustin, CA
Background/Purpose: In the ACTIVE phase III trial, postmenopausal women with osteoporosis were randomized 1:1:1 to abaloparatide (ABL; n=824), blinded placebo (PBO; n=821), or open-label teriparatide…
Abstract Number: 1891 • 2017 ACR/ARHP Annual Meeting
Low Alkaline Phosphatase Levels: Could It be Hypophosphatasia?
C. Tornero¹, P. Aguado¹, S. García-Carazo¹, J.A. Tenorio², P. Lapunzina², K. Heath², A. Buño³, J.M. Iturzaeta³, Irene Monjo⁴, C. Plasencia¹ and Alejandro Balsa¹, ¹Rheumatology, Rheumatology. La Paz University Hospital, Spain., Madrid, Spain, ²Institute of Medical and Molecular Genetics (INGEMM), Institute of Medical and Molecular Genetics (INGEMM). La Paz University Hospital, Spain., Madrid, Spain, ³Laboratory medicine, Laboratory medicine. La Paz University Hospital, Spain., Madrid, Spain, ⁴Rheumatology, Rheumatology. La Paz University Hospital, Spain., MADRID, Spain
Background/Purpose: Hypophosphatasia (HPP) is a rare inherited disorder caused by mutations in ALPL (alkaline phosphatase liver type ALPL gene). Clinical presentation is variable and adult…
Abstract Number: 1892 • 2017 ACR/ARHP Annual Meeting
A20 Haploinsufficiency: Clinical Phenotypes and Disease Course of Patients with This Newly Recognized Autoinflammatory Disease
Florence A. Aeschlimann¹, Ezgi Deniz Batu², Ellen Go³, Ahmet Gül⁴, Patrycja M. Hoffmann⁵, Helen L. Leavis⁶, Seza Ozen⁷, Annet van Royen-Kerkof⁶, Daniella Schwartz⁸, Deborah L. Stone⁹, Ivona Aksentijevich¹⁰, Daniel L. Kastner¹¹ and Ronald Laxer¹, ¹Rheumatology, The Hospital for Sick Children, University of Toronto, Toronto, ON, Canada, ²Pediatric Rheumatology, Hacettepe University Faculty of Medicine, Ankara, Turkey, ³Pediatrics, Indiana University School of Medicine, Indianapolis, IN, ⁴Department of Internal Medicine, Division of Rheumatology, Istanbul University, Istanbul Faculty of Medicine, Istanbul, Turkey, ⁵Inflammatory Disease Section, National Human Genome Research Institute, Bethesda, MD, ⁶Pediatric Immunology, University Medical Center Utrecht, Utrecht, Netherlands, ⁷Department of Pediatrics, Division of Rheumatology, Hacettepe University Faculty of Medicine, Ankara, Turkey, ⁸NIAMS - Rheumatology, National Institutes of Health, Bethesda, MD, ⁹Inflammatory Disease Section, NHGRI/NIH, Bethesda, MD, ¹⁰National Human Genome Research Institute, National Institutes of Health, Inflammatory Disease Section, Bethesda, MD, ¹¹Inflammatory Disease Section, National Human Genome Research Institute, National Institutes of Health, Bethesda, MD
Background/Purpose: Haploinsufficiency of A20 (HA20) is a newly discovered autoinflammatory disease caused by mutations in TNFAIP3. A20 is a protein with a crucial role in…
Abstract Number: 1893 • 2017 ACR/ARHP Annual Meeting
Pharmacokinetics (PK), Pharmacodynamics (PD), and Proposed Dosing of Oral Janus Kinase (JAK)1 and JAK2 Inhibitor Baricitinib in Patients with IFN-Mediated Autoinflammatory Diseases (AIDs)
Hanna Kim¹, Kristina M. Brooks², Paul Wakim³, Mary Blake⁴, Stephen R. Brooks⁵, Gina A. Montealegre Sanchez⁶, Adriana Almeida de Jesus⁶, Yan Huang⁶, Wanxia Li Tsai⁷, Massimo G. Gadina⁴, Parag Kumar² and Raphaela Goldbach-Mansky⁶, ¹Pediatric Translational Research Branch, NIAMS/NIH, Bethesda, MD, ²Clinical Pharmacokinetics Research Unit, Pharmacy Department, NIH Clinical Center, Bethesda, MD, ³Biostatistics and Clinical Epidemiology Service, NIH Clinical Center, Bethesda, MD, ⁴Translational Immunology Section, Office of Science and Technology, NIAMS/NIH, Bethesda, MD, ⁵Biodata Mining and Discovery Section, Office of Science and Technology, NIAMS/NIH, Bethesda, MD, ⁶Translational Autoinflammatory Disease Studies (TADS), Laboratory of Clinical Investigation and Microbiology (LCIM), NIAID/NIH, Bethesda, MD, ⁷Translational Immunology, Office of Science and Technology, NIAMS/NIH, Bethesda, MD
Background/Purpose: JAK inhibitors reduce IFN-signaling ex vivo. We evaluated the PK and PD of the oral JAK1 and JAK2 inhibitor, baricitinib, from data collected in…
Abstract Number: 1894 • 2017 ACR/ARHP Annual Meeting
Genetic Phenotypes Impacting Efficacy and Safety of Canakinumab in Patients with Colchicine-Resistant FMF, TRAPS and Hids/Mkd: Results from Cluster Study
Fabrizio De Benedetti¹, Paivi Miettunen², Tilmann Kallinich³, Gerd Horneff⁴, Riva Brik⁵, Alberto Tomassini⁶, Takahiro Yasumi⁷, Sinisa Savic⁸, Ivan Foeldvari⁹, Liora Harel¹⁰, Romina Gallizzi¹¹, Antonio Speziale¹², Guido Junge¹² and Marco Gattorno¹³, ¹Division of Rheumatology, IRCCS Bambino Gesù Children's Hospital, Rome, Rome, Italy, ²Alberta Children's Hospital Research Institute/University of Calgary, Calgary, AB, Canada, ³Charité, Humbolt University Medicine Berlin, Berlin, Germany, ⁴Asklepios Kliniken GmbH, Hamburg, Germany, ⁵Pediatrics, Rambam Medical Center, Haifa, Israel, ⁶Institute for Maternal and Child Health- IRCCS “Burlo Garofolo”, Trieste, Italy, ⁷Department of Pediatrics, Kyoto University Graduate School of Medicine, Kyoto, Japan, ⁸University of Leeds, Leeds, United Kingdom, ⁹Hamburger Zentrum für Kinder-und Jugend Rheumatologie, Hamburg, Germany, ¹⁰Schneider Children's Medical Center of Israel, Sackler School of Medicine, Tel Aviv University, Tel Aviv, Israel, ¹¹Department of Pediatrics, University of Messina, Messina, Italy, ¹²Novartis Pharma AG, Basel, Switzerland, ¹³Pediatric Rheumatology, G. Gaslini Institute, Genoa, Italy
Background/Purpose: Familial Mediterranean fever (FMF), Hyper IgD Syndrome (HIDS)/mevalonate kinase deficiency (MKD) and TNF-receptor associated periodic syndrome (TRAPS) are monogenic auto-inflammatory diseases caused by mutations…
Abstract Number: 1895 • 2017 ACR/ARHP Annual Meeting
Serum Interleukin 18 As a Biomarker for Systemic Juvenile Idiopathic Arthritis and Macrophage Activation Syndrome and Use of Recombinant Human IL-18 BP in a Patient with Refractory Disease
Shima Yasin¹, Rachel Brown¹, Ndate Fall², Krista Solomon¹, Scott Canna³, Charlotte Girard⁴, Cem Gabay⁵, Eduardo Schiffrin⁶, Andrew Sleight⁶, Alexei A. Grom⁷ and Grant Schulert⁸, ¹Pediatric Rheumatology, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, ²Division of Rheumatology, Cincinnati Children's Hospital, Cincinnati, OH, ³NIAMS, National Institutes of Health, Bethesda, MD, ⁴Division of Rheumatology, Department of Internal Medicine Specialties, University Hospital of Geneva, Geneva, Switzerland, ⁵SCQM, Geneva, Switzerland, Geneva, Switzerland, ⁶AB2 Bio, Lausanne, Switzerland, ⁷Division of Pediatric Rheumatology, Cincinnati Children’s Hospital Medical Center, Cincinnati, OH, United States Minor Outlying Islands, ⁸Pediatric Rheumatology, Division of Pediatric Rheumatology, Cincinnati Children’s Hospital Medical Center, Cincinnati, OH
Background/Purpose: Systemic juvenile idiopathic arthritis is an autoinflammatory childhood arthritis with prominent innate immune activity. Macrophage activation syndrome is a severe and potentially fatal complication…
Abstract Number: 1896 • 2017 ACR/ARHP Annual Meeting
IL-18 As a Diagnostic Biomarker, Differentiating Systemic JIA from Acute Leukaemia, Severe Bacterial Infections and Other Auto-Immune Disorders
Arjen Leek¹, Nienke Ter Haar², Valerie De Haas³, Ayman El Idrissi¹, Judith Wienke¹, Sytze de Roock⁴, Dirk Holzinger⁵, Wilco de Jager⁶, Jorg van Loosdregt⁷ and Sebastiaan Vastert^4,8, ¹Pediatric Rheumatology and Immunology, University Medical Center Utrecht, Utrecht, Netherlands, ²Department of Pediatric Rheumatology and immunology, University Medical Center Utrecht, Utrecht, Netherlands, ³DCOG Laboratory, SKION, Den Haag, Netherlands, ⁴Laboratory of Translational Immunology, University Medical Center Utrecht, Utrecht, Netherlands, ⁵Department of Pediatric Rheumatology and Immunology, University of Muenster, Muenster, Germany, ⁶Dept Immunology, UMC Utrecht, Utrecht, Netherlands, ⁷Laboratory for Translational immunology, University Medical Center Utrecht, Utrecht, Netherlands, ⁸Division of Pediatric Rheumatology, University Medical Center Utrecht, Utrecht, Netherlands
Background/Purpose: Systemic onset Juvenile Idiopathic Arthritis (sJIA) is a disease characterized by systemic inflammation in addition to arthritis and it’s diagnosis currently still depends on…
Abstract Number: 1897 • 2017 ACR/ARHP Annual Meeting
the Ferritin to ESR Ratio: A Simple Measure to Distinguish Macrophage Activation Syndrome from Systemic Arthritis Flare
Esraa M. A. Eloseily^1,2, Francesca Minoia³, Timothy Beukelman², Angelo Ravelli⁴ and Randy Q. Cron², ¹Pediatrics, Assiut University, Assiut, Egypt, ²Pediatric Rheumatology, University of Alabama at Birmingham, Birmingham, AL, ³Istituto Giannina Gaslini, Genoa, Italy, ⁴University of Genova, Genova, Italy
Background/Purpose: Macrophage activation syndrome (MAS) is a life threatening complication of systemic juvenile idiopathic arthritis (sJIA). As MAS often shares clinical and laboratory features with…
Abstract Number: 1898 • 2017 ACR/ARHP Annual Meeting
Overweight/Obesity Affect Histological Features of Synovial Membrane of Rheumatoid Arthritis Patients from Disease Onset to Stable Remission Achievement
Stefano Alivernini¹, Barbara Tolusso¹, Maria Rita Gigante¹, Laura Bui², Clara Di Mario¹, Luca Petricca¹, Gabriele Di Sante¹, Roberta Benvenuto², Anna Laura Fedele¹, Francesco Federico², Gianfranco Ferraccioli³ and Elisa Gremese¹, ¹Institute of Rheumatology, Fondazione Policlinico Universitario A. Gemelli - Catholic University of the Sacred Heart, Rome, Italy, ²Institute of Pathology, Fondazione Policlinico Universitario A. Gemelli - Catholic University of the Sacred Heart, Rome, Italy, ³Institute of Rheumatology, Università Cattolica - Fondazione Policlinico Universitario A.Gemelli, Rome, Italy
Background/Purpose: Despite animal models, little is known about synovial tissue (ST) composition of overweight/obese Rheumatoid Arthritis patients. The aim of the study was to investigate…
Abstract Number: 1899 • 2017 ACR/ARHP Annual Meeting
Osteopontin and Leptin Are Associated with Erosive Disease in an Inception Cohort of Rheumatoid Arthritis Treated-to-Target with Combination Conventional DMARD Therapy
Mihir D. Wechalekar^1,2,3, Susan Lester⁴, Sunil Nagpal⁵, Suzanne Cole⁶, Jessica Peters⁷, Anuk Das⁸, Pravin Hissaria⁹, Tania Crotti¹⁰, Catherine Hill^1,11,12, Sudha Raghunath¹³, Llew Spargo¹⁴, Jennifer G Walker^13,14,15, Malcolm D. Smith² and Susanna Proudman^1,10, ¹Rheumatology Unit, Royal Adelaide Hospital, Adelaide, Australia, ²Flinders University, Adelaide, Australia, ³Rheumatology Unit, Repatriation General Hospital, Adelaide, Australia, ⁴Queen Elizabeth Hospital, Adelaide, Australia, ⁵Immunology, Janssen Research & Development, Spring House, PA, ⁶Immunology, Janssen Research and Development, Spring House, PA, ⁷Janssen Research & Development, Spring House, PA, ⁸Janssen R&D, Berwyn, PA, ⁹Immunology, SA Pathology, Adelaide, Australia, ¹⁰University of Adelaide, Adelaide, Australia, ¹¹Medicine, The University of Adelaide, Adelaide, Australia, ¹²The Queen Elizabeth Hospital, Adelaide, Australia, ¹³Repatriation General Hospital, Adelaide, Australia, ¹⁴Rheumatology Unit, Royal Adelaide Hospital, South Australia, Adelaide, Australia, ¹⁵Flinders University of South Australia, Adelaide, Australia
Background/Purpose: We sought to identify biomarkers associated with erosive disease and bone loss in an inception rheumatoid arthritis (RA) cohort receiving treat-to-target combination DMARD therapy…
Abstract Number: 1900 • 2017 ACR/ARHP Annual Meeting
Effect of Age and Body Mass Index (BMI) on Multi-Biomarker Disease Activity (MBDA) Score in Patients with Rheumatoid Arthritis
Kerri Ford¹, David Chernoff¹, Xingbin Wang¹, Eric H. Sasso¹, Carol J. Etzel^2,3 and Dimitrios A. Pappas^3,4, ¹Crescendo Bioscience Inc., South San Francisco, CA, ²Departments of Epidemiology and Biostatistics, University of Texas School of Public Health, Houston, TX, ³Corrona, LLC, Southborough, MA, ⁴Columbia University, New York, NY
Background/Purpose: We evaluated the associations between MBDA score and age and between MBDA score and BMI in patients with rheumatoid arthritis (RA). These relationships may…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].